Patient Stratification and Monitoring of ACTAIR® Treatment Efficacy Using New Objective Immune Markers (Trial Not Registered)

Actair study

This trial is Coming soon
Registration number Trial Not Registered
Investigated initiated study - prospective controlled (three-arm) trial of 18 months of Actair (extended to 36 months total) whereby patients who had a clinical history of perennial rhinitis confirmed with a HDM skin prick of >5mm and serum HDM specific IgE > class 3 were recruited. Now a further extension of the study has been approved to include patients who are currently receiving a licensed house dust mite sublingual immunotherapy tablet (Actair or Acarizax) treatment for 2 or 3 years.

Program & service

This trial is being run with the Heart & Lung service, and as part of the Respiratory program.

Trial phase

Other

Trial participation type

This trial is for clinical research of something other than a drug or device.

Principal investigator

Prof Mark Hew

Key inclusion data

Patients must currently be taking a licensed HDM sublingual tablet (Actair or Acarizax) and be near completion of treatment at either 2 years or 3 years of treatment.

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.